From: Social, economic, and health impact of the respiratory syncytial virus: a systematic search
Topics | References* | |
---|---|---|
Incidence | [18],[20],[21],[23]-[26],[29],[31],[32],[43],[54],[55] | |
Prevalence | [23],[70],[75] | |
Impact on health | Respiratory infections | [21],[25]-[27],[29],[31],[32],[35],[36],[75],[84] |
Wheezing and asthma | [20],[22],[28],[41]-[45],[51],[67],[75],[79],[83],[85]-[95],[105] | |
Allergic rhinoconjunctivitis | [41],[45],[79],[95] | |
Mortality | [18],[20],[22],[24],[46],[47],[49]-[51],[63],[67],[82] | |
Acute otitis media | [51]-[53] | |
Apneas | [31],[33],[67],[73] | |
Neurological involvement | [48],[73] | |
Cardiac involvement | [73] | |
COPD | [35]-[40] | |
Other | [28],[31],[41],[42],[45],[48],[51],[52],[56],[67],[73],[79],[84] | |
Risk factors | [20],[21],[41],[47],[70],[80],[103] | |
Impact on use of resources | Primary care visits | [20],[22],[34],[51] |
Emergency room visits | [22],[34],[51] | |
Hospital visits | [22],[34],[41],[51] | |
Hospital admissions | [18],[20]-[26],[29],[30],[32],[34],[41],[46],[47],[49],[51],[54]-[56],[63],[65],[66],[77],[78],[80],[81],[96]-[101] | |
UCI admissions | [20]-[22],[24],[29],[32],[34],[41],[47],[48],[52],[56],[63],[65],[77],[78],[101] | |
Diagnostic tests | [21],[22],[30],[56] | |
Ventilation | [22],[24],[29],[31],[48],[49],[56],[63],[77],[78],[101] | |
Treatment | [22],[26],[30],[34],[74],[77],[102] | |
Impact on costs | Direct costs | [34],[41],[51],[55],[57]-[63],[70] |
Indirect costs | [41],[59]-[63] | |
Strategies to reduce impact | Hygienic measures | [41],[49],[71],[104] |
Prophylactic treatment | [19],[21],[34],[41],[46],[48],[49],[52],[55],[57]-[65],[69],[70],[72],[74],[76]-[78],[105],[106] | |
Spain | [21],[25],[26],[29],[30],[41],[47],[48],[58]-[60],[63],[64],[77],[80] | |
Adults | [22],[24],[35]-[40],[50],[54],[75] |